The first conflicting results of randomized controlled trials (RCTs) on anti-IL-6 monoclonal antibodies in COVID-19 [86–90] did not show a significant mortality benefit for treatment with tocilizumab in moderately ill hospitalized patients, while a decreased risk of mechanical ventilation has been found [91]. Here, IL6 is linked to COVID-19.